INT 230-6

Drug Profile

INT 230-6

Alternative Names: INT-230-6

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Intensity Therapeutics
  • Class Cancer vaccines; Platinum complexes; Vinca alkaloids
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 15 Jun 2017 Intensity Therapeutics has patents pending for INT 230-6 in Australia
  • 15 Jun 2017 Intensity Therapeutics receives patent allowance for its DfuseRxSM technology platform in USA
  • 02 Mar 2017 INT 230-6 is available for licensing as of 02 Mar 2017. http://www.intensitytherapeutics.com/index.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top